Abstract
Conophylline (CNP) has various biological activities, such as insulin production. A recent study identified ADP-ribosylation factor-like 6-interacting protein 1 (ARL6ip1) as a direct target protein of CNP. In this study, we revealed that ARL6ip1 is a three-spanning transmembrane protein and determined the CNP-binding domain of ARL6ip1 by deletion mutation analysis of ARL6ip1 with biotinyl-amino-CNP. These results suggest that CNP is expected to be useful for future investigation of ARL6ip1 function in cells. Because of the anti-apoptotic function of ARL6ip1, CNP may be an effective therapeutic drug and/or a novel chemosensitizer for human cancers and other diseases.
Original language | English |
---|---|
Pages (from-to) | 3656-3660 |
Number of pages | 5 |
Journal | FEBS Letters |
Volume | 587 |
Issue number | 22 |
DOIs | |
Publication status | Published - 2013 Nov 15 |
Keywords
- ARL6ip1
- Conophylline
- Redox-sensitive luciferase assay
- Topology
ASJC Scopus subject areas
- Biophysics
- Structural Biology
- Biochemistry
- Molecular Biology
- Genetics
- Cell Biology